Jefferies Financial Group Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $3.00

Sangamo Therapeutics (NASDAQ:SGMO) had its target price lowered by Jefferies Financial Group from $7.00 to $3.00 in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on SGMO. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Thursday, December 19th. Barclays raised their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. StockNews.com downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Truist Financial upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Friday, December 13th. Finally, Wells Fargo & Company reduced their price target on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.50.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $1.13 on Tuesday. The firm has a market capitalization of $235.77 million, a P/E ratio of -1.51 and a beta of 1.15. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18. The business has a fifty day moving average of $2.14 and a 200 day moving average of $1.22.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. During the same period in the previous year, the company posted ($0.34) EPS. Analysts expect that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Large investors have recently added to or reduced their stakes in the company. Meritage Portfolio Management lifted its position in Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 6,740 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 38,850 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Sangamo Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after purchasing an additional 57,125 shares during the period. XTX Topco Ltd boosted its stake in shares of Sangamo Therapeutics by 167.8% in the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 64,981 shares during the last quarter. Finally, Golden State Equity Partners grew its stake in shares of Sangamo Therapeutics by 35.2% during the 3rd quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 69,368 shares during the period. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.